- Tesla reported a 2% decline in third-quarter electric-vehicle deliveries amid a broader U.S. market slowdown and a pivot toward robotaxis and AI.
- Novartis agreed to license a messenger RNA drug candidate from China's Abogen in a deal valued at up to $7.8 billion.
- Bayer announced a $2.2 billion investment to expand its U.S. pharmaceutical manufacturing with a new site in Ohio.